Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.

ClinicalTrials.gov 4 recruiting now full pipeline small index

Leiomyoma: full-pipeline trial registry

4 of 9 indexed Leiomyoma trials are currently recruiting.

Corpus placement: #1,916 of 28,707 conditions by registered trial count.

9 US clinical trials · 4 currently recruiting · #1,916 of 28,707 conditions by registered trial count

Leiomyoma: 9 US clinical trials tracked, 4 recruiting.

Leiomyoma is the subject of 9 registered US clinical trials on ClinicalTrials.gov, 4 of them currently open to new participants. 3 are in Phase 3-4 (later-stage) and 3 in Phase 1-2 (earlier-stage). The most active sponsor is Johns Hopkins University, running 2 of these trials.

Enrollment posture brief

Registry condition leiomyoma

OPEN 4 | RECR 44% | LATE 3 | EARLY 3 | RANK #1916 | SPON 2

Nearest open-share peer: Acute Ischemic Stroke (44% recruiting · 27 trials)

Acute Lymphoblastic Leukemia55.6%Acute Respiratory Distress S55.6%Leiomyoma (this)44%Acute Otitis Media22.2%Acute Heart Failure11.1%
Open-enrollment share among volume-matched conditions near Leiomyoma

Leiomyoma lists 4 open slots (44% of 9 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →

Key findings

What ClinicalTrials.gov does not surface for Leiomyoma on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.

  1. Leiomyoma is recruiting below its size-band peers.

    4 of 9 indexed trials (44.4%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.

  2. One sponsor concentrates Leiomyoma research.

    Johns Hopkins University accounts for 2 of 9 trials (22.2%). 8 distinct sponsors appear on at least one study for this condition label.

  3. Typical Leiomyoma enrolment sits around 72 participants.

    Median target enrolment is 72 among the 9 trials that report a genuine target (sentinel values excluded). 5 of those (55.6%) plan for fewer than 100 participants.

  4. Leiomyoma research is mostly interventional.

    8 interventional and 1 observational studies make up this index (88.9% interventional). Study type is sponsor-reported on ClinicalTrials.gov.

Phase 23Phase 32Phase 41

Open and recent trials

9 total, page 1 of 1

Phase Distribution

PhaseTrial count
Phase 2 3
Phase 3 2
Phase 4 1

Named interventions

Most-linked intervention names on Leiomyoma records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.

Inert Capsule Drug
1 trials
CDB-2914 Drug
1 trials
Ulipristal acetate (UPA) Drug
1 trials
ulipristal acetate 10 mg Drug
1 trials
ulipristal acetate 20 mg Drug
1 trials
Abdominal hysterectomy Procedure
1 trials
Laparoscopic hysterectomy Procedure
1 trials
Placebo 40 mg Drug
1 trials

US sites by state

Facility locations filed on Leiomyoma trials. A trial with sites in several states counts in each.

Maryland 4 trials
California 2 trials
Texas 1 trials
New York 1 trials
Nevada 1 trials
Nebraska 1 trials
North Carolina 1 trials
Mississippi 1 trials

Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.

What to do with this Leiomyoma page

9 registered trials, 4 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Leiomyoma condition card totals 9 registered trials; most-linked intervention Inert Capsule; top US site state Maryland. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.